Skip to Content

Doxorubicin Transdrug: Significant increased survival rate in patients with advanced hepatocellular carcinoma treated in a phase II clinical trial

PARIS--(BUSINESS WIRE)--Dec 8, 2009 - BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces positive survival data in its phase II clinical trial with doxorubicin Transdrug® in patients with advanced hepatocellular carcinoma (primary liver cancer).

Doxorubicin Transdrug®, a treatment presented in the form of nanoparticles delivered via hepatic intra-arterial route, was granted an orphan drug status in Europe and in the United States. The product is being evaluated in patients with advanced hepatocellular carcinoma, one of the leading causes of mortality in cancer.

BioAlliance Pharma phase II results showed a 88.9% survival rate after 18 months of treatment in patients having received three intra-arterial doxorubicin Transdrug® injections, as per protocol. This increased survival rate is relevant compared to the 54.5% rate observed in patients with the current standard of care (usually transarterial chemoembolisation with a cytotoxic drug).

Based on these data, BioAlliance Pharma will design new approaches using doxorubicin Transdrug® while reducing pulmonary adverse events that led to the suspension of the trial.

“BioAlliance Pharma is capitalizing on its proprietary Transdrug® nanotechnology by developing oral drug formulations”, said Dominique Costantini, President and CEO of BioAlliance Pharma. “We are applying this innovative know-how to the treatment of various cancers using oral irinotecan nanoparticles instead of intravenously administration. BioAlliance Pharma aims at improving the irinotecan's risk-benefit ratio and has recently presented positive preclinical data at several international symposia”, added Dominique Costantini.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at


This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website ( or on BioAlliance Pharma S.A.'s website (



Contact: BioAlliance Pharma SA
Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
Caroline Carmagnol
Tel.: +33 6 64 18 99 59

Posted: December 2009